Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

NCT01716754 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

471

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: QGE031
DRUG: Omalizumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals